ClinVar Miner

Submissions for variant NM_000492.3(CFTR):c.3808G>A (p.Asp1270Asn) (rs11971167)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000176372 SCV000602988 pathogenic Hereditary pancreatitis 2018-05-15 criteria provided, single submitter clinical testing The CFTR c.3808G>A, p.Asp1270Asn variant (rs11971167) has been reported in patients diagnosed with congenital bilateral absence of vas deferens (CBAVD), in trans with p.Phe508del (Anguiano 1992, Oates 1993), but is more commonly found in a complex allele (with p.Arg74Trp and p.Val201Met) in patients with CBAVD and pancreatitis (Bareil 2007, Casals 1995, Masson 2013, Steiner 2011). In individuals where the p.Asp1270Asn alone was reported in trans with p.Phe508del, they had normal or slightly elevated sweat chloride levels (Anguiano 1992, Padoa 1999). Functional characterization of the p.Asp1270Asn variant indicates reduced overall mRNA and protein expression (van Goor 2014), reduced chloride conductance (Sosnay 2013, van Goor 2014) and altered response patterns (Fanen 1999). However, protein maturation and glycosylation is comparable to wildtype (Fanen 1999, Sosnay 2013, van Goor 2014). This variant is found in the general population with an overall allele frequency of 0.1% (315/276666 alleles, including 3 homozygotes) in the Genome Aggregation Database. The aspartate at residue 1270 is highly conserved, and computational algorithms ( PolyPhen-2, SIFT) predict that the variant has an impact on the protein. Based on the above information, the variant is classified as very mildly pathogenic.
Counsyl RCV000046985 SCV000795824 uncertain significance Cystic fibrosis 2017-11-19 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000587433 SCV000228017 uncertain significance not provided 2018-05-11 criteria provided, single submitter clinical testing
GeneDx RCV000587433 SCV000568550 uncertain significance not provided 2017-12-05 criteria provided, single submitter clinical testing The D1270N variant in the CFTR gene has been reported previously in trans with the common delta F508 pathogenic variant in an individual with normal sweat chloride levels, a normal chest roentgenogram but who had CAVD (Anguiano et al., 1992). Expression studies in HeLa and FRT cells showed that D1270N transfected cells displayed decreased chloride transport activity compared to wild type cells (Fanen et al., 1999; Van Goor et al., 2014). However, D1270N has also been identified unaffected individuals who were compound heterozygous for D1270N and a definitively pathogenic variant (Sugarman et al., 2014). The D1270N variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret D1270N as a variant of uncertain significance.
Integrated Genetics/Laboratory Corporation of America RCV000587433 SCV000696992 uncertain significance not provided 2016-12-15 criteria provided, single submitter clinical testing Variant summary: The CFTR c.3808G>A (p.Asp1270Asn) variant involves the alteration of a conserved nucleotide. 4/5 in silico tools predict a damaging outcome for this substitution. This variant was found in 405/139526 control chromosomes (1 homozygote) at a frequency of 0.0029027, which does not exceed the estimated maximal expected allele frequency of a pathogenic CFTR variant (0.0129603). The variant has been reported in patients with CF, CBAVD, lung cancer, idiopathic chronic pancreatitis and recurrent respiratory infections. This variant almost always co-occurs on the same allele with R74W, a variant whose pathogenicity is unclassified (although the functional study done by Fanen_1999 indicated R74W as polymorphism). The variant's complex forms p.[R74W;D1270N] and p.[R74W;V201M;D1270N] are associated with CBAVD as well as is a third complex p.[R74W; R1070W;.D1270N]. The complex of the variant does not cause CF in females when found at compound heterozygous state with a disease-causing mutation such as p.Phe508del (Verlingue_1993; Claustres_2000) but the same genotype may cause CBAVD in males. Functional studies showed that variant with defective cAMP-activated chloride conductance activity, decreased CFTR maturation, as well as defective chloride transport function compared with WT protein (Fanen_1999.pdf, Van Goor_2013), suggesting functional effect at the protein level. Clinical laboratories classifiy this variant as VUS via C;invar (without evidence to independently evaluate). Sosnay_2013 classified the disease liability of this variant as indeterminate based upon an evaluation of clinical severity, functional consequence, disease penetrance in 2188 fathers of individuals with CF. Because none of the patients reported with CF or CF-related phenotypes have been reported with this variant in isolation, the variant is classidied as a VUS.
Invitae RCV000046985 SCV000074998 benign Cystic fibrosis 2017-11-16 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000480239 SCV000967180 likely benign not specified 2018-07-18 criteria provided, single submitter clinical testing The p.Asp1270Asn variant in CFTR has been reported in isolation or as part of th e p.[Arg74Trp;Asp1270Asn] complex allele in several individuals with CFTR-relate d conditions (Aguiano 1992, Casals 1995, Fanen 1999, Padoa 1999, Ravnik-Glavac 2 000, Luzardo 2002, Girodon 2002, Masson 2013, Sosnay 2013, Terlizzi 2017, Behar 2017). However, it has also been identified in isolation in trans with known pat hogenic CFTR variants in 2 unaffected adult male individuals and as part of the p.[Arg74Trp;Asp1270Asn] allele in trans with a known pathogenic variant in 1 una ffected child (Terlizzi 2017). It has also been identified with the p.Val201Met allele as part of the p.[Arg74Trp;Val201Met;Asp1270Asn] complex allele in severa l individuals with CFTR-related conditions who carried additional pathogenic var iants in CFTR (Claustres 20004, Brugnon 2008, de Prada Merino 2010, Steiner 2011 , Masson 2013, Terlizzi 2017). However, the p.[Arg74Trp;Val201Met;Asp1270Asn] al lele has also been identified in trans with the p.Phe508del in twin boys who are reportedly unaffected, although the paper did not specify if they were examined for CBAVD (Brugnon 2008). In addition, the p.Asp1270Asn variant has been identi fied in 1.3% (315/24024) of African chromosomes, including 3 homozygotes, by the Genome Aggregation Database (gnomAD, In sum mary, the p.Asp1270Asn variant in isolation or as part of the p.[Arg74Trp;Asp127 0Asn] complex allele is classified as likely benign based on the high allele fre quency and the presence of this variant in trans with known pathogenic variants in unaffected individuals, though the clinical significance of the p.[Arg74Trp;V al201Met;Asp1270Asn] complex allele is uncertain. ACMG/AMP Criteria applied: BS1 , BP2.
OMIM RCV000007584 SCV000027785 pathogenic Congenital bilateral absence of the vas deferens 1992-04-01 no assertion criteria provided literature only
PharmGKB RCV000660771 SCV000783010 drug response ivacaftor response - Efficacy 2018-03-23 reviewed by expert panel curation PharmGKB Level of Evidence 1A: Annotation for a variant-drug combination in a CPIC or medical society-endorsed PGx guideline, or implemented at a PGRN site or in another major health system.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000480239 SCV000601108 uncertain significance not specified 2016-08-12 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.